← brief for 2026-09-06 · Slowing decline

Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA.

Key takeaways

Some people have blood pressure that stays high on three drugs, which is called resistant hypertension. Guidelines say to add a drug like spironolactone next, but this study looked at what happened when doctors added a GLP-1 drug instead, in patients who were overweight or had obesity. It used records from many US centers, looking backward at care that already happened. That design shows a link between the drug choice and later blood pressure, heart, and kidney outcomes, not proof that one drug caused a better result.

Who did this work

Tian Z · Willerding JM · Schmidt-Ott KM · Melk A · Schmidt BMW

Source

Article · PubMed, the drug frontier · 2026 Aug 29
https://pubmed.ncbi.nlm.nih.gov/42701458/